(ISIN Nos.: US886516AC70 and USP91528AA03; CUSIP Nos.: 886516AC7 and P91528AA0) TIERRA DEL FUEGO, Argentina, Dec. 11, 2023 /PRNewswire/ — The Province of Tierra del Fuego (the “Province“) today announced that as of 5:00 p.m. (New York City time) on December 11, 2023, 69.36% of holders of Outstanding (as defined below) Notes had validly delivered consents pursuant… Continue reading The Province of Tierra del Fuego Extends Expiration Time of its Consent Solicitation
Category: Newswire
ROSEN, THE FIRST FILING FIRM, Encourages Barclays PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – BCS, BCLYF
NEW YORK, Dec. 11, 2023 /PRNewswire/ — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Barclays PLC (NYSE: BCS) (OTC: BCLYF) between July 22, 2019 and October 12, 2023, both dates inclusive (the “Class Period”), of the important January 2, 2024 lead plaintiff deadline in the securities class… Continue reading ROSEN, THE FIRST FILING FIRM, Encourages Barclays PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – BCS, BCLYF
US Contact Lenses Market Projections and Key Trends to 2028: Exponential Growth in Eye Health Technologies
DUBLIN, Dec. 11, 2023 /PRNewswire/ — The “US Contact Lenses Market Outlook to 2028” report has been added to ResearchAndMarkets.com’s offering. The latest comprehensive research publication on the US Contact Lenses Market provides an in-depth analysis of the industry, with a spotlight on the significant growth expected over the next five years. The market, which is… Continue reading US Contact Lenses Market Projections and Key Trends to 2028: Exponential Growth in Eye Health Technologies
ROSEN, A LEADING LAW FIRM, Encourages AdaptHealth Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AHCO
NEW YORK , Dec. 11, 2023 /PRNewswire/ — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of AdaptHealth Corp. (NASDAQ: AHCO) between (1) August 4, 2020 and February 27, 2023, both dates inclusive (the “Class Period”) and/or (2) AdaptHealth common stock pursuant and/or traceable to the Company’s secondary public offering… Continue reading ROSEN, A LEADING LAW FIRM, Encourages AdaptHealth Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AHCO
Vistra Prices Upsized Private Offerings of $400 Million of Senior Secured Notes and $350 Million of Senior Notes; Upsizes Cash Tender Offers to $750 Million
IRVING, Texas, Dec. 11, 2023 /PRNewswire/ — Vistra Corp. (NYSE: VST) (the “Company” or “Vistra”) announced today the pricing of upsized private offerings of $400 million aggregate principal amount of 6.950% senior secured notes due 2033, which form a part of the same series of the Issuer’s (as defined below) outstanding 6.950% Senior Secured Notes due… Continue reading Vistra Prices Upsized Private Offerings of $400 Million of Senior Secured Notes and $350 Million of Senior Notes; Upsizes Cash Tender Offers to $750 Million
ROSEN, NATIONAL TRIAL LAWYERS, Encourages General Motors Company Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – GM
NEW YORK, Dec. 11, 2023 /PRNewswire/ — WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of General Motors Company (NYSE: GM) between February 2, 2022 and October 26, 2023, both dates inclusive (the “Class Period”). A class action lawsuit has… Continue reading ROSEN, NATIONAL TRIAL LAWYERS, Encourages General Motors Company Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – GM
ROSEN, A LEADING LAW FIRM, Encourages Expensify, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – EXFY
NEW YORK, Dec. 11, 2023 /PRNewswire/ — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Expensify, Inc. (NASDAQ: EXFY) pursuant and/or traceable to the Offering Documents issued in connection with the Company’s Initial Public Offering conducted on or about November 11, 2021 (“IPO” or “Offering”) (the “Class… Continue reading ROSEN, A LEADING LAW FIRM, Encourages Expensify, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – EXFY
Global Linear Motion Systems Industry Report, 2022 and 2023-2030: Smart Mechatronics & Linear Motion Systems Go together to Clear Path for Industry 4.0
DUBLIN, Dec. 11, 2023 /PRNewswire/ — The “Linear Motion Systems – Global Strategic Business Report” report has been added to ResearchAndMarkets.com’s offering. Global Linear Motion Systems Market to Reach $4.4 Billion by 2030 The global market for Linear Motion Systems estimated at US$2.8 Billion in the year 2022, is projected to reach a revised size of… Continue reading Global Linear Motion Systems Industry Report, 2022 and 2023-2030: Smart Mechatronics & Linear Motion Systems Go together to Clear Path for Industry 4.0
Treatment with CARVYKTI® (ciltacabtagene autoleucel) Resulted in Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Disease-Specific Symptoms in Patients with Earlier-Line Multiple Myeloma
Oral presentations at the 2023 ASH Annual Meeting include patient-reported outcomes from the CARTITUDE-4 study and longer-term efficacy and safety data from CARTITUDE-2 study cohorts A and B, show the promise of CARVYKTI® in earlier lines of treatment SAN DIEGO, Dec. 11, 2023 /PRNewswire/ — Johnson & Johnson announced today new patient-reported outcomes (PRO) from… Continue reading Treatment with CARVYKTI® (ciltacabtagene autoleucel) Resulted in Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Disease-Specific Symptoms in Patients with Earlier-Line Multiple Myeloma
Updated Data from the BRUIN Phase 1/2 Study of Pirtobrutinib in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Presented at the 2023 ASH Annual Meeting
INDIANAPOLIS, Dec. 11, 2023 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced updated clinical data from the international Phase 1/2 BRUIN trial of pirtobrutinib, a non-covalent (reversible) Bruton’s tyrosine kinase (BTK) inhibitor, in adult patients with a range of B-cell malignancies. These data, which were presented in oral and poster presentations at the… Continue reading Updated Data from the BRUIN Phase 1/2 Study of Pirtobrutinib in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Presented at the 2023 ASH Annual Meeting